Immatics Nv Stock Performance
| IMTX Stock | USD 7.18 0.09 1.24% |
The company retains a Market Volatility (i.e., Beta) of 0.6, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immatics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Immatics is expected to be smaller as well. At this point, Immatics NV has a negative expected return of -0.77%. Please make sure to check out Immatics' information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immatics NV performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immatics NV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 148.5 M |
Immatics |
Immatics Relative Risk vs. Return Landscape
If you would invest 1,219 in Immatics NV on September 18, 2024 and sell it today you would lose (497.00) from holding Immatics NV or give up 40.77% of portfolio value over 90 days. Immatics NV is currently does not generate positive expected returns and assumes 2.8701% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Immatics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immatics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immatics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immatics NV, and traders can use it to determine the average amount a Immatics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2691
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMTX |
Estimated Market Risk
| 2.87 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immatics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immatics by adding Immatics to a well-diversified portfolio.
Immatics Fundamentals Growth
Immatics Stock prices reflect investors' perceptions of the future prospects and financial health of Immatics, and Immatics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immatics Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Current Valuation | 379.44 M | ||||
| Shares Outstanding | 121.55 M | ||||
| Price To Earning | 44.61 X | ||||
| Price To Book | 2.19 X | ||||
| Price To Sales | 12.37 X | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) | ||||
| Cash And Equivalents | 324.38 M | ||||
| Cash Per Share | 5.00 X | ||||
| Total Debt | 15.4 M | ||||
| Debt To Equity | 0.13 % | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Earnings Per Share | (0.64) X | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
About Immatics Performance
Evaluating Immatics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immatics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immatics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.Things to note about Immatics NV performance evaluation
Checking the ongoing alerts about Immatics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immatics NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immatics NV generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 54 M. Net Loss for the year was (96.99 M) with profit before overhead, payroll, taxes, and interest of 172.83 M. | |
| About 69.0% of the company shares are owned by institutional investors |
- Analyzing Immatics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immatics' stock is overvalued or undervalued compared to its peers.
- Examining Immatics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immatics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immatics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immatics' stock. These opinions can provide insight into Immatics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.